Does Amazon Own the Liability When FBA Ships an Unapproved Drug?

TL;DR

• Company: Amazon.com, Inc., Seattle, WA — cited as the entity that introduced three unapproved drug products into interstate commerce via Fulfillment by Amazon, not merely as a marketplace host.
• Date: FDA Warning Letter, Reference/MARCS-CMS 728814, issued June 17, 2026; posted to fda.gov June 23, 2026.
• Classification: CDER — Unapproved New Drugs/Misbranded.
• Key citations: FD&C Act §§ 301(d) and 505(a) (21 U.S.C. §§ 331(d), 355(a)); "new drug" status under 21 U.S.C. § 321(p); disease-treatment claims as evidence of intended use under 21 CFR 201.128.
• Consequence: 15-business-day response window; as of this writing, FDA has not posted a public response letter or close-out for this warning letter.

The easy assumption is that when an illegal drug shows up for sale online, the company on the hook is whoever manufactured it, not whoever's website it appeared on. FDA's June 17, 2026 warning letter to Amazon.com, Inc., Reference/MARCS-CMS 728814, tests that assumption directly. It is addressed not to a manufacturer but to Andy Jassy, CEO of Amazon.com, Inc., at the company's Seattle headquarters. And the reason it lands on Amazon rather than a third-party seller is a single fulfillment detail buried in the letter's opening paragraphs.

Three purchases, one fulfillment method

In May 2026, FDA investigators purchased three products directly on www.amazon.com: "Vajraang Phimosis Mini Combo," "Penile Heal Cream," and "Beilloso Balanitis Relief Cream." All three arrived through Fulfillment by Amazon (FBA), the program under which sellers ship inventory to Amazon's warehouses and Amazon itself picks, packs, and ships the order to the customer.

That mechanic is the crux of the letter. On a typical third-party marketplace listing, Amazon operates the storefront but a separate seller ships the product, and FDA's enforcement letters over the years have generally landed on that seller. FBA changes who touches the box. When Amazon fulfills the order, Amazon is the party that physically introduces and delivers the product into interstate commerce, the exact conduct the Food, Drug, and Cosmetic Act regulates. FDA's letter treats the three test purchases as proof of exactly that: Amazon, not an anonymous third-party seller, moved these drugs from a warehouse shelf to a customer's door.

What made these three products "drugs" FDA could act on

None of the three products carry FDA approval. That alone is not automatically a violation. What converts an unapproved product into an actionable one is labeling that makes disease-treatment claims, which FDA treats as evidence of "intended use" under 21 CFR 201.128. The letter quotes the labeling directly:

• "FOR PHIMOSIS"
• "Phimosis & Paraphimosis cream"
• "Coconut Oil for Phimosis"
• "Daily Phimosis Cream"
• "Helps relieve redness, itching & irritation from balanitis"
• "Balanitis Relief Cream"

Each phrase promises to treat, mitigate, or relieve a named medical condition, phimosis or balanitis, rather than describing a cosmetic or general wellness use. Under 21 CFR 201.128, that kind of labeling is itself evidence of the product's intended use, regardless of what ingredients the product actually contains or how mild they might be.

The legal theory, plainly stated

Once labeling establishes disease-treatment intent, FDA's statutory path is direct. A product intended to treat, cure, or prevent disease that has not gone through FDA's approval process is a "new drug" under 21 U.S.C. § 321(p). New drugs cannot lawfully enter interstate commerce without an approved application, per FD&C Act § 505(a), 21 U.S.C. § 355(a), unless they are generally recognized as safe and effective (GRASE) for their labeled use, a status FDA determined none of the three products holds. Introducing or delivering such a product into interstate commerce violates FD&C Act §§ 301(d) and 505(a), 21 U.S.C. §§ 331(d) and 355(a). FDA's letter frames the purchases as conducted "as part of FDA's public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs," the same rationale the agency cites in nearly every unapproved-new-drug letter, applied here to a fulfillment relationship rather than a manufacturing one.

Why this letter reads differently than a CGMP case

Every other database entry in this pipeline traces back to a manufacturing-side failure: a contaminated aseptic line, a fabricated lab result, a quality system that stopped functioning. This letter cites no manufacturing defect at all. FDA never inspected a production facility here, and the letter does not allege the products were made unsafely. The violation is entirely about distribution: labeling that makes disease claims, paired with a distribution channel, FBA, that puts Amazon itself in the chain of introduction rather than a seller Amazon merely hosts.

That distinction is why this letter is worth reading even for compliance teams with no connection to Amazon. It is the first warning letter in this pipeline's coverage built entirely around marketplace fulfillment liability rather than manufacturer CGMP failure. For any company that uses FBA, or any platform that fulfills third-party inventory on a seller's behalf, the letter is a data point that FDA is willing to treat the fulfillment operator, not just the brand on the label, as the party that "introduced" a product into commerce.

What happens next, and what isn't known yet

FDA's letter carries the same procedural mechanics as any other warning letter: Amazon has 15 business days from receipt to respond in writing, detailing the specific steps taken to correct the violations and prevent recurrence. The letter states that failure to promptly and adequately address the violations may result in regulatory or legal action, including seizure and injunction, without further notice.

As of this writing, no public FDA response letter or close-out notice has been posted for Reference/MARCS-CMS 728814. The record does not show whether or how Amazon responded, whether the three named products were removed from sale, or whether FDA considers the matter resolved. Anyone tracking this case should treat the response as an open question, not an assumed outcome, until FDA publishes something further.

What compliance and legal teams should take from it

Two things travel beyond this specific letter. First, the FBA distinction matters more than it might seem. A company that only lists on a marketplace and ships from its own warehouse faces a different liability posture than one that hands inventory to a fulfillment program where the platform itself picks, packs, and ships. FDA's letter treats that difference as legally significant, not incidental.

Second, the underlying labeling problem here is a familiar one dressed in an unfamiliar distribution channel. Disease-treatment language on a topical cream, "for phimosis," "balanitis relief," is the same category of claim that has drawn FDA unapproved-new-drug letters against dietary supplements, cosmetics, and OTC products for years. What's new is that the letter reaches through the marketplace layer to the fulfillment operator instead of stopping at the individual seller's storefront.

FAQ

What did FDA's warning letter to Amazon.com, Inc. cite?

FDA cited Amazon for introducing three unapproved new drugs, "Vajraang Phimosis Mini Combo," "Penile Heal Cream," and "Beilloso Balanitis Relief Cream," into interstate commerce in violation of FD&C Act §§ 301(d) and 505(a) (21 U.S.C. §§ 331(d), 355(a)). All three products were purchased directly on www.amazon.com in May 2026 and fulfilled through Fulfillment by Amazon (FBA), in Reference/MARCS-CMS 728814, issued June 17, 2026.

Why is Amazon named in this letter instead of the individual product sellers?

Because all three products were fulfilled through FBA, meaning Amazon itself shipped the orders from its own fulfillment network rather than a third-party seller shipping directly. FDA's letter treats that fulfillment role as the act of introducing and delivering the products into interstate commerce, the conduct the FD&C Act regulates, rather than treating Amazon as a neutral marketplace host.

What made these three products "unapproved new drugs" rather than ordinary cosmetics?

Their labeling made disease-treatment claims, phrases like "FOR PHIMOSIS," "Phimosis & Paraphimosis cream," and "Helps relieve redness, itching & irritation from balanitis." Under 21 CFR 201.128, labeling that promises to treat or relieve a named medical condition is evidence of the product's intended use. Because that intended use is disease treatment and none of the products has FDA approval or GRASE status, they meet the definition of "new drugs" under 21 U.S.C. § 321(p) and cannot lawfully be marketed without an approved application.

Has Amazon responded to this warning letter?

As of this writing, FDA has not posted a public response letter or close-out notice for Reference/MARCS-CMS 728814. The record does not show whether or how Amazon has responded. The letter gave Amazon 15 business days from receipt to submit its written response.

Source: FDA Warning Letter, Reference/MARCS-CMS 728814, June 17, 2026. Byline: Andy Gaber, Founder. Published 2026-07-16.

Get FDA briefs — $99/mo →